The latest news from Neuromics, customers, collaborators, and friends. Here we will post publications, data, new reagents, and methods. 

For additional information on Neuroscience updates check out our Neuroscience Blog

New Antibodies

Neuromics is excited to tell you about new antibodies to our catalog. 

Image: Immunofluorescent analysis of (A) C6 rat glioma cells and (B) Human embryonic kidney cells stained with mouse mAb to fibrillarin, MO22169, dilution 1:1,000 in red, in both cases costained with chicken pAb to vimentin, CH22108, dilution 1:10,000 in green. The blue is DAPI staining of nuclear DNA.

Read More

Your Opinion Matters

We enjoy hearing from researcher using Neuromics solutions. Leave us a review and you could be eligible for a $10 Starbucks. 

Leave a Review 

Read More

May News

Save on the BBB Model

We kick off May by offering $700 off our most popular Blood-Brain Barrier Model. You can now purchase our 12-well model for only $1900. Only valid thru 5/31/2018

Buy Now

Read More

HUVECS in 3-D Action

Form Vascular Networks in Microfluidics Model

In this study, the authors developed a 3D functional human microvascular network in a microfluidic device. The established model enables Neuromics GFP-labeled human umbilical vein endothelial cellsto form vessel-like microtissues and have physiological functions which are closer to cells in human blood vessels. The perfusable microvasculature allows the delivery of nutrients, and oxygen, as well as flow-induced mechanical stimuli into the luminal space of the endothelium. The microflow effectively mimic the blood flow in human vessels.

Read More

Antibodies You Can Trust

Neuromics specialize in providing reagents and methods for the Neuroscience, Immunology, Cancer, Stem Cell and Regenerative Medicine Research Community.  We serve scientists doing basic research and drug discovery in Neurodegenerative Diseases, Pain, Autoimmune Diseases and Cancer. Our unique value is based on providing reagents that are thoroughly tested and characterized.

Read More